Terminated OBSERVATIONAL NCT05259072

carDIo-ttranSSfOrm nucLEar Imaging Study (DISSOLvE)

Sponsor: Ionis Pharmaceuticals, Inc.

Conditions Amyloidosis Transthyretin Amyloid Cardiomyopathy

Interventions 99m-technetium pyrophosphate scintigraphy

Updated 4 times since 2022 Last updated: Jan 25, 2025 Started: Jan 19, 2022 Primary completion: Dec 30, 2023 Completion: Dec 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Rolled over into another study

Other terminated trials from Ionis Pharmaceuticals, Inc.

More terminations from Ionis Pharmaceuticals, Inc.

Other Amyloidosis trials with similar outcome

Browse all Amyloidosis trials

This observational or N/A phase trial investigates Amyloidosis and Transthyretin Amyloid Cardiomyopathy and is currently terminated or withdrawn. Ionis Pharmaceuticals, Inc. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Feb 2025 — Present [monthly]

Terminated

Status: Recruiting → Terminated · Phase: PHASE3 → None
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE3
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Mar 2022 — Jul 2024 [monthly]

Recruiting PHASE3

First recorded

Jan 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ionis Pharmaceuticals, Inc.
Oregon Health and Science University

Data source: Oregon Health and Science University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States